March 2026 Thermo Fisher Scientific Inc. continued expanding its research antibody and life sciences solutions portfolio through brands such as Invitrogen™ and Thermo Scientific™. The company continued developing antibody reagents, immunoassay solutions, and research tools supporting biomedical research, diagnostics development, and drug discovery.
February 2026 Abcam plc (Danaher Corporation) continued strengthening its antibody research portfolio, including validated antibodies, recombinant antibodies, and assay-ready research products for academic, pharmaceutical, and biotechnology researchers.
January 2026 Bio-Rad Laboratories Inc. continued expanding its life science research portfolio, including antibodies, immunoassay reagents, and protein analysis solutions used in cell biology, molecular research, and biotechnology applications.
November 2025 Merck KGaA (MilliporeSigma) continued advancing its antibody and life science reagent portfolio, providing research antibodies, assay reagents, and laboratory solutions for pharmaceutical, academic, and biotechnology applications.
October 2025 Cell Signaling Technology (CST) continued expanding its research antibody portfolio, including highly validated antibodies for signaling pathways, cancer biology, immunology, and molecular biology research.